Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Exceptional extension!
Enjoy this offer
* See conditions under "Our services"

Valuation: Satellos Bioscience Inc.

Market Cap 120M 104M 96.73M 90.69M 170M 11.29B 171M 1.15B 444M 5.56B 449M 440M 19.33B P/E 2026 *
-3.35x
P/E 2027 * -3.58x
Enterprise Value 26.1M 22.77M 21.08M 19.77M 37M 2.46B 37.26M 250M 96.76M 1.21B 97.97M 95.87M 4.21B EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
93.51%
Yield 2026 *
-
Yield 2027 * -
1 day+0.25%
1 week+1.62%
Current month-19.31%
1 month-17.68%
3 months-19.47%
6 months-0.12%
Current year+2.90%
1 week 7.86
Extreme 7.86
8.27
1 month 7.86
Extreme 7.86
10.26
Current year 7.67
Extreme 7.67
18.98
1 year 6.36
Extreme 6.36
18.98
3 years 3.48
Extreme 3.48
18.98
5 years 2.58
Extreme 2.58
22.8
10 years 2.58
Extreme 2.58
22.8
Manager TitleAgeSince
Chief Executive Officer 70 2018-02-28
Chief Tech/Sci/R&D Officer - 2018-04-30
Director of Finance/CFO - 2023-08-31
Director TitleAgeSince
Director/Board Member 76 2023-06-28
Chairman 59 2018-06-30
Director/Board Member 56 2025-11-13
Date Insider Type Main position Quantity % Market Cap.
04-06Buy

Director

5,500 0.0356%
04-06Buy

Director

4,500 0.0291%
04-06Option

Founder

108,630 0.7027%
Change 5-day change 1-year change 3-year change Capi.($)
+0.25%+1.62%+23.48%+30.61% 120M
+1.44%-1.25%+64.25%+114.23% 55.19B
+4.60%+3.02%+57.38%+48.98% 45.75B
-1.44%+0.39%-14.68%-17.33% 22.98B
-2.69%-2.10%-6.70%+374.02% 20.76B
+3.22%-0.84%+27.88%-20.46% 16.26B
+0.58%+1.08%+18.85%-37.32% 15.42B
-1.01%-2.30%+28.59%+174.08% 13.05B
+4.95%+11.70%+125.78%+252.19% 12.45B
+3.07%+0.14%+29.05% - 12.37B
Average +1.30%+2.17%+35.39%+102.11% 21.44B
Weighted average by Cap. +1.63%+1.48%+40.77%+101.10%

Financials

2026 *2027 *
Net sales - -
Net income -46.27M -40.37M -37.37M -35.04M -65.59M -4.36B -66.05M -443M -172M -2.15B -174M -170M -7.47B -57.06M -49.78M -46.09M -43.21M -80.88M -5.38B -81.45M -546M -212M -2.65B -214M -210M -9.21B
Net Debt -93.65M -81.7M -75.64M -70.92M -133M -8.83B -134M -897M -347M -4.35B -352M -344M -15.12B -111M -97.14M -89.94M -84.32M -158M -10.5B -159M -1.07B -413M -5.17B -418M -409M -17.97B
Logo Satellos Bioscience Inc.
Satellos Bioscience Inc. is a Canada-based clinical-stage drug development company. The Company is focused on restoring natural muscle repair and regeneration in degenerative muscle diseases. Through its research, the Company has developed SAT-3247, a first-of-its-kind, orally administered small molecule drug designed to address deficits in muscle repair and regeneration. SAT-3247 targets AAK1, a key protein that has identified as capable of replacing the signal normally provided by dystrophin in muscle stem cells to effect repair and regeneration. It is also leveraging its proprietary discovery platform MyoReGenX to identify additional muscle diseases or injury conditions where restoring muscle repair and regeneration may have therapeutic benefit and represent future clinical development opportunities. With this platform, the Company is building a pipeline of therapeutics to correct muscle stem cell polarity and promote the body’s innate muscle repair and regeneration process.
Employees
20
Date Price Change Volume
26-06-19 8.150 $ +0.25% 3,406
26-06-18 8.130 $ +0.12% 3,216
26-06-17 8.120 $ +2.92% 8,970
26-06-16 7.890 $ -1.38% 19,143
26-06-15 8.000 $ -0.25% 11,569
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
8.150CAD
Average target price
15.33CAD
Spread / Average Target
+88.14%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. MSCL Stock
-40%: Exceptional extension
d
:
:
SEIZE THE OFFER!